-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

Benzinga·10/01/2026 12:33:43
Listen to the news
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.